Even as pan­dem­ic re­cedes, short-staffed tri­al sites leave can­cer pa­tients wait­ing

Illustration: Assistant editor Kathy Wong for Endpoints News

In the ear­ly days of the Covid-19 pan­dem­ic, when many tri­als were ground­ed, Ja­son Luke and his fel­low clin­i­cal re­searchers at the Uni­ver­si­ty of Pitts­burgh Med­ical Cen­ter were still test­ing new can­cer drugs in 50 Phase I stud­ies. Now, his col­leagues on­ly have the band­width to han­dle one-fifth the amount of ear­ly-stage tri­als as they did in ear­ly 2021.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.